Guerbet SA (EPA:GBT)

Market Cap	84.43M -54.6%
Revenue (ttm)	790.65M -3.7%
Net Income	-140.56M
EPS	-11.20
Shares Out	12.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,945
Open	6.60
Previous Close	6.60
Day's Range	6.56 - 6.73
52-Week Range	5.80 - 18.26
Beta	1.09
Analysts	Sell
Price Target	7.65 (+13.67%)
Est. Earnings	Mar 11, 2027

About Guerbet

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1901
• Employees: 2,746
• Stock Exchange: Euronext Paris
• Ticker Symbol: GBT

Analyst Summary

According to 2 analysts, the average rating for GBT stock is "Sell." The 12-month stock price target is €7.65, which is an increase of 13.67% from the latest price.

Price Target

€7.65

(13.67% upside)

Analyst Consensus: Sell

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error